Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines

International Archives of Occupational and Environmental Health

Volumn 87, Issue 7, 2014, Pages 715-724

  Pesch, Beate ^a   Taeger, Dirk ^a   Johnen, Georg ^a   Gawrych, Katarzyna ^a   Bonberg, Nadine ^a   Schwentner, Christian ^b   Wellhäußer, Harald ^c   Kluckert, Matthias ^a,c   Leng, Gabriele ^d   Nasterlack, Michael ^e   Lotan, Yair ^f   Stenzl, Arnulf ^b   Brüning, Thomas ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c INSTITUT FÜR ARBEITSSCHUTZ DER DEUTSCHEN GESETZLICHEN UNFALLVERSICHERUNG IFA   (Germany)

^d Bayer Industry Services GmbH and Co OHG   (Germany)

^e BASF SE   (Germany)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aromatic amines; Bladder cancer; Chemical workers; Cytology; NMP22; Screening; UroVysion; Validation study

Indexed keywords

AMINE; NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TUMOR MARKER;

ADULT; AGED; ANALYSIS; HUMAN; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE;

ADULT; AGED; AMINES; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OCCUPATIONAL EXPOSURE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84909990608     PISSN: 03400131     EISSN: 14321246     Source Type: Journal    
DOI: 10.1007/s00420-013-0916-3     Document Type: Article

References (41)

1. Abd El Gawad I, Moussa HS, Nasr MI, El Gemae EH, Masooud AM, Ibrahim IK, El Hifnawy NM (2005) Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst 17:193–202
2. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF et al (2013) Results of the two incidence screenings in the national lung screening trial. N Engl J Med 369:920–931
3. Aravidis C, Panani AD, Kosmaidou Z, Thomakos N, Rodolakis A, Antsaklis A (2012) Detection of numerical abnormalities of chromosome 9 and p16/CDKN2A gene alterations in ovarian cancer with fish analysis. Anticancer Res 32:5309–5313
4. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008
5. Banek S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Gawrych K, Bonberg N, Johnen G, Kluckert M et al (2012) Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-study. Urol Oncol. doi:10.1016/j.urolonc.2012.04.015
6. Behrens T, Bonberg N, Casjens S, Pesch B, Brüning T (2013) A practical guide to epidemiological practice and standards in the identification and validation of diagnostic markers using a bladder cancer example. BBA Proteins Proteomics. doi:10.1016/j.bbpap.2013. Article first published online: 18 July 2013
7. Bonberg N, Taeger D, Gawrych K, Johnen G, Banek S, Schwentner C, Sievert KD, Wellhausser H, Kluckert M, Leng G et al (2013) Chromosomal instability and bladder cancer—the UroVysion™ test in the UroScreen study. BJU Int. doi:10.1111/j.1464-410X.2012.11666.x
8. Brenner DE, Normolle DP (2007) Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum. Cancer Epidemiol Biomarkers Prev 16:1918–1920
9. Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, Litwin MS (2011) Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 117:5392–5401
10. FDA, U.S.Federal Food and Drug Administration (2000) NMP22. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num=P940035S002. Accessed 29 May 2013
11. FDA, U.S.Federal Food and Drug Administration (2005) UroVysion. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num=P030052. Accessed 29 May 2013
12. Fischer CG, Waechter W, Kraus S, Fuentecilla PE, Weidner W, Dudeck J (1998) Urologic tumors in the Federal Republic of Germany: data on 56,013 cases from hospital cancer registries. Cancer 82:775–783
13. Freudenthal RI, Stephens E, Anderson DP (1999) Determining the potential of aromatic amines to induce cancer of the urinary bladder. Int J Toxicol 18:353–359
14. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y (2005) Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293:810–816
15. Hemstreet GP III, Yin S, Ma Z, Bonner RB, Bi W, Rao JY, Zang M, Zheng Q, Bane B, Asal N et al (2001) Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 93:427–436
16. Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M et al (2012) Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int 110:699–708
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
18. Johnen G, Gawrych K, Bontrup H, Pesch B, Taeger D, Banek S, Kluckert M, Wellhausser H, Eberle F, Nasterlack M et al (2012) Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen. PLoS One 7:e35363
19. Klorin G, Rozenblum E, Glebov O, Walker RL, Park Y, Meltzer PS, Kirsch IR, Kaye FJ, Roschke AV (2013) Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines. Cancer Genet 206:191–205
20. Kumara-Siri MH, Shapiro LE, Surks MI (1986) Association of the 3,5,3'-triiodo-L-thyronine nuclear receptor with the nuclear matrix of cultured growth hormone-producing rat pituitary tumor cells (GC cells). J Biol Chem 261:2844–2852
21. Larre S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB (2013) Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol 63:1049–1058
22. Lokeshwar VB, Schroeder GL, Selzer MG, Hautmann SH, Posey JT, Duncan RC, Watson R, Rose L, Markowitz S, Soloway MS (2002) Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 95:61–72
23. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP III, Bono AV, Getzenberg RH, Goebell P, Schmitz-Drager BJ et al (2005) Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology 66:35–63
24. Lotan Y, Shariat SF (2008) Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 101:1362–1367
25. Lotan Y, Svatek RS, Sagalowsky AI (2006) Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 107:982–990
26. Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI (2009a) Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 103:1368–1374
27. Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, Sagalowsky AI (2009b) Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 182:52–57
28. Nasterlack M, Scheuermann B, Messerer P, Pallapies D, Zober A (2001) Harnblasenkrebs in einem Risikokollektiv: Klinische und epidemiologische Aspekte. Symp Med 12:17–19
29. Panani AD, Maliaga K, Babanaraki A, Bellenis I (2009) Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer. Anticancer Res 29:4483–4487
30. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100:1432–1438
31. Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, Feil G, Johnen G, Ickstadt K, Kluckert M et al (2011) The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int 108:546–552
32. Ransohoff DF (2013) Cultivating cohort studies for observational translational research. Cancer Epidemiol Biomarkers Prev 22:481–484
33. Rehn L (1895) Blasengeschwülste bei Fuchsin-Arbeitern. Archiv für Klinische Chirurgie 50:588–600
34. Sauter G, Algaba F, Amin M, Busch C, Cheville J, Gasser T, Grignon D, Hofstaedter F, Lopez-Beltran A, Epstein J (2004) Noninvasive urothelial neoplasias: WHO classification of noninvasive papillary urothelial tumors. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs, 3rd edn. IARC Press, Lyon
35. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI (2008) Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10:120–135
36. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 162:53–57
37. Sullivan P, Chan J, Levin M, Rao J (2010) Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res 2:412–440
38. Todenhoefer T, Hennenlotter J, Witstruk M, Gakis G, Aufderklamm S, Kuehs U, Stenzl A, Schwentner C (2012) Influence of renal excretory function on the performance of urine based markers to detect bladder cancer. J Urol 187:68–73
39. van Rhijn BW, van der Poel HG, Van der Kwast TH (2005) Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47:736–748
40. Vineis P, Pirastu R (1997) Aromatic amines and cancer. Cancer Causes Control 8:346–355
41. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE et al (2011) A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) 4:375–383